Novateor Research Laboratories schedules board meeting for Sep 3

scanx
Reviewed by
Shriram SScanX News Team
Key Highlights
  • Novateor Research Laboratories schedules board meeting for September 3, 2026
  • Agenda includes approval of matters for the ensuing annual general meeting
  • Disclosure made pursuant to Regulation 29 of SEBI LODR Regulations, 2015
  • Meeting to be held at the registered office in Ahmedabad
powered bylight_fuzz_icon
49739976

*this image is generated using AI for illustrative purposes only.

Novateor Research Laboratories Limited has scheduled a board meeting for September 3, 2026. The session will address the upcoming annual general meeting and other corporate governance matters.

The company issued the intimation on August 31, 2026, in compliance with Regulation 29 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The meeting is set to take place at the company's registered office in Ahmedabad.

Agenda Details

The board of directors will consider the following items during the session:

  • Approval of matters related to the ensuing annual meeting of the company
  • Transaction of any other business with the prior approval of the chairman

Navdeep Subhashbha Mehta, Managing Director, digitally signed the disclosure. The company's registered office is located at Dev Atelier in Prahladnagar, Ahmedabad.

Historical Stock Returns for Novateor Research Laboratories

1 Day5 Days1 Month6 Months1 Year5 Years
-2.59%0.0%0.0%0.0%-2.85%0.0%

What specific financial results or dividend proposals are expected to be presented at the ensuing annual general meeting?

Are there any anticipated changes to the board composition or executive leadership during this governance review?

How might the outcomes of this meeting influence Novateor's strategic direction in the pharmaceutical research sector for the upcoming fiscal year?

Novateor Research Laboratories
View Company Insights
View All News
like20
dislike

Novateor Research Laboratories receives Rs 8.4 lakh order from Smart Laboratories

scanx
Reviewed by
Ritika DScanX News Team
Key Highlights

Novateor Research Laboratories discloses a Rs 8.4 lakh purchase order for teeth whitening serum. With zero TTM revenue, book-to-bill metrics are unavailable. Valuation shows high P/E vs low ROCE.

powered bylight_fuzz_icon
48751101

*this image is generated using AI for illustrative purposes only.

WHAT HAPPENED

Novateor Research Laboratories has entered into a Marketer and Manufacturer agreement with Smart Laboratories Private Limited. As part of this arrangement, the company received a Purchase Order valued at Rs 8.4 lakh for the supply of 10,000 units of Advance Teeth Whitening Serum. The execution timeline for this order is specified as one month.

ORDER IN FINANCIAL CONTEXT

The disclosed order value of Rs 8.4 lakh is nominal relative to the company's reported trailing twelve-month revenue of Rs 0.0 crore. Because the revenue base is zero, the book-to-bill ratio and backlog coverage in quarters are not computable. The "Total Disclosed Order Book" figure sums exactly the same last 3 fiscal quarters shown in the order track record table below (no wider window). The first time this total appears, add a short parenthetical confirming this, e.g. (sum of the N orders disclosed across the last 3 fiscal quarters shown in the table below). Use the exact order count from the "Total Disclosed Order Book" line in the pre-computed context. Since no previous orders were disclosed in the last three fiscal quarters, this single filing represents the entirety of the recent order track record.

COMPANY ORDER TRACK RECORD

No previous order disclosures were found for Novateor Research Laboratories in the last three fiscal quarters. This current filing marks the first recorded order inflow in this period, making it impossible to assess whether inflow velocity is accelerating or decelerating. The per-order size of Rs 8.4 lakh cannot be compared against historical averages due to the absence of prior data.

EXECUTION AND REVENUE QUALITY

The company's consolidated financials show Rs 0.0 crore in revenue and net profit for the trailing twelve months, with an operating profit margin of 0.0%. Without positive revenue generation, it is not possible to determine if existing backlog is converting to revenue at an improving rate. The lack of profitability signals that the company is either in early-stage operations or facing significant execution challenges.

Quarter: Revenue (Rs Cr): Net Profit (Rs Cr): OPM (%):
TTM 0.0 0.0 0.0%

WORKING CAPITAL AND EXECUTION CAPACITY

Balance sheet and cashflow data are not provided in the input, preventing an assessment of liquidity, current ratio, or operating cashflow. Future filings should be monitored for details on working capital requirements and the ability to fund production for new orders.

WHAT TO WATCH

  • Execution rate: Monitor whether the Rs 8.4 lakh order converts into recognized revenue within the stated one-month timeline.
  • Revenue recognition: Given the zero TTM revenue base, any positive quarterly revenue will be a key milestone for validating commercial traction.
  • Order volume: Watch for subsequent disclosures to determine if this is an isolated transaction or the start of a consistent order flow.
  • Margin quality: Assess the operating profit margin on executed orders to understand the profitability of the Marketer and Manufacturer model.

KEY OBSERVATIONS

  • Valuation check (as of 20 Aug 2026): P/E of 193.2x against ROCE of 1.68%. At the time of this article, valuation was pricing in execution improvement not yet visible in return ratios. (P/E is price-derived and will change; ROCE is from audited financials)
  • Revenue base: Trailing twelve-month revenue is Rs 0.0 crore, which limits the utility of traditional order-book metrics like book-to-bill ratio.
  • Order history: No orders were disclosed in the past three fiscal quarters, making this filing the sole reference point for recent contract activity.

Historical Stock Returns for Novateor Research Laboratories

1 Day5 Days1 Month6 Months1 Year5 Years
-2.59%0.0%0.0%0.0%-2.85%0.0%
Novateor Research Laboratories
View Company Insights
View All News
like20
dislike

More News on Novateor Research Laboratories

1 Year Returns:-2.85%